| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8817381 | Annals of Medicine and Surgery | 2017 | 37 Pages |
Abstract
In Europe, clinical trials involving cultured ASCs and/or the use of collagenase, which causes changes in the structural and functional properties of stem cells, and/or ASCs application in non-homologous tissue, should be considered off-label. ASCs should be non-cultured, isolated mechanically, and used only in the subcutaneous tissue.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Public Health and Health Policy
Authors
Francesco Simonacci, Nicolò Bertozzi, Edoardo Raposio,